Fulcrum Therapeutics (NASDAQ:FULC) Stock Price Up 6.5% – Should You Buy?

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) were up 6.5% during mid-day trading on Thursday . The stock traded as high as $11.42 and last traded at $11.6540. Approximately 66,428 shares changed hands during trading, a decline of 90% from the average daily volume of 662,627 shares. The stock had previously closed at $10.94.

Analysts Set New Price Targets

FULC has been the topic of several recent research reports. Piper Sandler restated an “overweight” rating and issued a $23.00 price target (up previously from $16.00) on shares of Fulcrum Therapeutics in a research note on Monday, December 8th. Wall Street Zen cut Fulcrum Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, January 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a report on Thursday, January 22nd. Cantor Fitzgerald lifted their price target on Fulcrum Therapeutics from $15.00 to $24.00 and gave the stock an “overweight” rating in a research report on Monday, December 8th. Finally, The Goldman Sachs Group reissued a “positive” rating on shares of Fulcrum Therapeutics in a research report on Monday, December 8th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Fulcrum Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $19.11.

Fulcrum Therapeutics Stock Up 7.9%

The stock has a market capitalization of $638.99 million, a P/E ratio of -10.08 and a beta of 3.19. The business has a fifty day moving average price of $10.97 and a 200-day moving average price of $9.36.

Insider Activity at Fulcrum Therapeutics

In related news, Director Robert J. Gould sold 15,000 shares of the stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $11.87, for a total transaction of $178,050.00. Following the transaction, the director owned 469,864 shares in the company, valued at $5,577,285.68. This represents a 3.09% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Ra Capital Management, L.P. sold 4,175,139 shares of the firm’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $13.98, for a total transaction of $58,368,443.22. Following the completion of the sale, the insider owned 6,053,960 shares in the company, valued at $84,634,360.80. This represents a 40.82% decrease in their position. The SEC filing for this sale provides additional information. 7.00% of the stock is owned by insiders.

Institutional Trading of Fulcrum Therapeutics

Large investors have recently modified their holdings of the company. Braidwell LP lifted its stake in shares of Fulcrum Therapeutics by 1,294.7% in the 4th quarter. Braidwell LP now owns 3,061,222 shares of the company’s stock worth $34,622,000 after purchasing an additional 2,841,734 shares during the period. Siren L.L.C. bought a new stake in Fulcrum Therapeutics during the fourth quarter valued at approximately $22,054,000. First Turn Management LLC purchased a new stake in Fulcrum Therapeutics during the fourth quarter valued at approximately $21,406,000. GSK plc bought a new position in Fulcrum Therapeutics in the fourth quarter worth approximately $20,196,000. Finally, Adage Capital Partners GP L.L.C. boosted its stake in shares of Fulcrum Therapeutics by 53.0% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 4,589,000 shares of the company’s stock worth $31,572,000 after acquiring an additional 1,589,000 shares during the last quarter. Institutional investors own 89.83% of the company’s stock.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.